The website for professionals in Laboratory Medicine

Integrated colour calibration technology solution

FFEI, a global developer of award-winning digital pathology imaging solutions, has announced that its Sierra colour calibration technology has been integrated into Visiopharm’s viewer, for AI-based image analysis and workflow.

Visiopharm is on a mission to transform pathology through artificial intelligence (AI) and workflow standardisation. This now goes a step further by enabling pathologists to view digital tissue samples that are standardised to ground truth colour – using scanner agnostic, device-specific ICC profiles.

The ICC profile is seamlessly generated using the recently launched Sierra Validate & Standardise (VS) Profiler. Available as a package, Sierra VS-Profiler comprises a Sierra slide, Sierra VS-Analyser tool and FFEI’s proprietary algorithm that will generate high-accuracy, device-specific ICC profiles. Specifically, the accuracy of a given scanner is measured using an image of the Sierra slide. A unique ICC profile is then generated for that device to be integrated into manufacturing, QA process, AI systems and other workflows.

It is this ICC profile that can now be integrated into Visiopharm’s pathology workflow and will enable all images scanned to remain standardised and of ground truth colour when viewed using the Visiopharm Viewer platform. For pathologists they simply need to upload the ICC profile to Visiopharm. 

“With an increasing demand for standardisation across the digital pathology landscape, we are excited that industry innovators such as Visiopharm are embracing the specific need to standardise colour - incorporating FFEI’s patented Sierra technology, quantitative analysis and high-accuracy ICC profiling algorithm into Visiopharm’s industry leading viewer. This collaboration represents a first-in-kind, scanner-agnostic solution to a key QA issue for current and future users,” commented Dr Rick Salmon.

“With this important milestone for scanner agnostic calibration and troubleshooting, Visiopharm underpins its leading position in the field of digital pathology and becomes the first company supporting FFEI ICC profiling,” said Visiopharm chief technology officer Johan Doré. 

www.ffei.co.uk

Upcoming Events

Point of Care: Innovations

The Bristol - Harbourside (Doyle Collection) hotel
20 September 2022

Arab Lab Live 2022

Dubai International Convention & Exhibition Centre Dubai World Trade Centre - Trade Centre - Trade Centre 2 - Dubai - United Arab Emirates
24 - 26 October 2022

Lab Innovations 2022

Hall 2 NEC, Birmingham
2 & 3 November 2022

MEDICA 2022

Messe Düsseldorf D-40474 Düsseldorf, Stockumer Kirchstraße 61
14 - 17 November 2022

Meeting demand: the changing picture of diagnostics

The King's Fund, London, W1G 0AN
16 November 2022

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Point of Care: Innovations

The Bristol - Harbourside (Doyle Collection) hotel
20 September 2022

Arab Lab Live 2022

Dubai International Convention & Exhibition Centre Dubai World Trade Centre - Trade Centre - Trade Centre 2 - Dubai - United Arab Emirates
24 - 26 October 2022

Lab Innovations 2022

Hall 2 NEC, Birmingham
2 & 3 November 2022

MEDICA 2022

Messe Düsseldorf D-40474 Düsseldorf, Stockumer Kirchstraße 61
14 - 17 November 2022

Meeting demand: the changing picture of diagnostics

The King's Fund, London, W1G 0AN
16 November 2022

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2022 Step Communications Ltd. Registered in England. Registration Number 3893025